Positive Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations

NovaBiotics Ltd (“NovaBiotics”) announces that its oral therapy for cystic fibrosis (CF), Lynovex®, has met the study objectives of the CARE CF 1 clinical trial.

CARE CF 1 assessed the effects of two weeks of Lynovex treatment as an adjunct to standard of care therapy (SOCT) in CF, compared to placebo plus SOCT. This trial was designed to determine whether the inclusion of Lynovex capsules alongside SOCT lessened the clinical impact of exacerbations in adults with CF, as measured by symptom severity and levels of bacteria and inflammatory mediators in sputum and blood.  CARE CF 1 was a 6-arm study with the primary objectives of determining the optimal dose and regimen of Lynovex in patients with exacerbations of CF-associated lung disease and to further evaluate the safety and tolerability of Lynovex in exacerbating CF patients.  Continue reading Positive Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations

New Inhaled Antibiotic To Treat Respiratory Infections

https://www.europeanpharmaceuticalreview.com/news/67983/polyphor-antibiotic-murepavadin/

Polyphor launches the development of an inhaled antibiotic murepavadin

Polyphor Ltd has announced the development of an inhaled dosage form of its break­through antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections

New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria

Synspira’s Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis

Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, Continue reading New Drug Improves Effectiveness of Antibiotics against Drug-resistant Bacteria

New License for CFTR Activators and Inhibitors

Vanda Pharmaceuticals (VNDA), UCSF Enter License Agreement for CFTR Activators and Inhibitors

https://www.streetinsider.com/

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive Continue reading New License for CFTR Activators and Inhibitors

Cystic Fibrosis Step by Step: Building a Treatment Routine

In this video, Gunnar stresses the importance of building a routine in order to stay compliant with his treatments and remain healthy. He also reminds listeners to keep an open dialogue with their doctors and support teams at CF Clinics. Continue reading Cystic Fibrosis Step by Step: Building a Treatment Routine

Making it Matter Ep. 30 – Living with a Roommate

When people with cystic fibrosis head off to college the big decision is whether or not to live with a roommate. If we choose to live with roommates, for many of us it will be the first time we are very much sharing our cystic fibrosis with someone else. The need to perform Continue reading Making it Matter Ep. 30 – Living with a Roommate

Breathing in a Cure: Inhalable Ibuprofen on the Horizon

Researchers working on inhalable ibuprofen to treat cystic fibrosis

Ibuprofen: You can buy it at any drug store, and it will help with that stabbing headache or sprained ankle. One of the ways it does so is by reducing Continue reading Breathing in a Cure: Inhalable Ibuprofen on the Horizon

Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article

Pulmatrix, Inc. (NASDAQ:  PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight Continue reading Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article

Raptor Pharmaceutical Launches QUINSAIR™ in Europe

http://www.nasdaq.com/press-release/raptor-pharmaceutical-launches-quinsair-in-europe-20160411-00214

First-in-Class Inhaled Fluoroquinolone Therapy for Cystic Fibrosis Patients
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Continue reading Raptor Pharmaceutical Launches QUINSAIR™ in Europe

Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

http://finance.yahoo.com/news/raptor-announces-qualified-infectious-disease-113000057.html

Raptor Pharmaceutical Corp. (RPTP) today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to MP-376, the Continue reading Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin